Fosun Pharma

Conjustar, a protein-conjugated medicine developer that has rapidly built a robust R&D pipeline through a combination of introduction and independent research and development. it delivers more effective and safer new cancer therapy options to the majority of cancer patients.

Fosun Kite Biotechnology is a joint venture between Shanghai Fosun Pharmaceutical and Kite Pharma, dedicated to the development of immune cell therapy products aimed at treating cancer. The company focuses on innovative pharmaceuticals, particularly through its research into axicabtagene ciloleucel and kite-439. These therapies are designed for the treatment of B-cell lymphomas and leukemias, with an emphasis on delivering high-quality medicines to the medical industry.

VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

Bianjie.AI focuses on the research and development of blockchain technologies and application platforms, providing consulting services to enhance technological solutions. The company is dedicated to building a global Web 3.0 internet infrastructure that supports distributed business ecosystems. Its offerings include a blockchain development middleware, a service framework, a decentralized data exchange network, and a medical knowledge base. Bianjie.AI employs blockchain technology to facilitate the secure exchange of medical information and is also involved in interchain capabilities, non-fungible tokens (NFTs), big data, and privacy computing. Through its innovative products and services, Bianjie.AI aims to advance the application of blockchain across various industries.

Scolioscan specializes in the research and development of medical imaging technology, particularly focusing on three-dimensional (3D) ultrasound imaging solutions. The company provides equipment and tools designed to detect and prevent musculoskeletal chronic diseases, with an emphasis on scoliosis assessment. Scolioscan's innovative technology allows for safe evaluations without the use of radiation, offering alternatives for scoliosis screening, diagnosis, and disease tracking. Additionally, their solutions facilitate visual feedback and treatment evaluation, equipping orthopedic, rehabilitation, and sports medicine professionals with accurate assessment protocols for scoliosis.

Primelink Bio is a biotechnology firm focused on advancing drug delivery systems, particularly through the development of antibody-drug conjugates (ADCs). The company employs bioconjugation technology to create a diverse library of ADC drug candidates using a flexible and modular platform. This approach allows Primelink Bio to identify optimal drug compositions tailored to specific targets, enhancing treatment options for cancer patients. By innovating in the field of drug delivery, Primelink Bio aims to improve the efficacy of cancer therapies.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To address clients' therapeutic product demands at the pre-clinical, clinical, and commercial stages, the firm offers end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Fosun Xingmai is a scientific and technological innovation-oriented enterprise focusing on the research and development, production and sales of medical imaging and pathological artificial intelligence software and digital solutions. Its products mainly analyze medical images through the use of artificial intelligence technology.

ZuriMED Technologies AG is a Swiss-based company founded in 2015 that specializes in orthopedic biomechanics and sports medicine. Originating from the University of Zurich and ETH Zurich, the company focuses on innovative advancements in medical technologies for soft tissue repair. Its flagship product, the Surgical-Fiberlock technology, represents a significant breakthrough in surgical procedures, particularly for anterior cruciate ligament reconstruction. This technology functions like a surgical "sewing" machine, mechanically interlocking medical patch fibers into soft tissue. By streamlining the surgical process and eliminating the need for interference screws, ZuriMED's solutions enhance fixation strength and reduce the number of surgical steps, ultimately enabling faster patient recovery with less pain.

OncoCare Cancer Centre is the largest private oncology practice in Singapore, offers specialized facilities to care for cancer patients.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

UniXell Biotechnology is a developer of cell therapies utilizing human pluripotent stem cell technology. The company focuses on addressing unmet medical needs in neurodegenerative diseases, rare diseases, and tumors. UniXell has established multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology, and high-precision gene editing. These innovations enable the development of effective treatment solutions aimed at improving the lives of patients suffering from complex medical conditions. The company's proprietary intellectual property encompasses various aspects of stem cell preparation, cultivation, differentiation, and gene editing, positioning it as a leader in the advancement of cellular therapies.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

MitrAssist is a company focused on developing innovative solutions for mitral valve regurgitation (MR). It has created a minimally invasive mitral valve implant that enhances the functionality of the natural mitral valve without causing damage. This unique "valve-in-valve" approach allows the implant to work in harmony with the existing valve, offering a treatment option that is neither a repair nor a replacement. MitrAssist's technology addresses the challenges associated with MR and aims to provide a more effective treatment solution for patients. By improving upon current minimally invasive methods, MitrAssist seeks to deliver significant advantages in patient care and outcomes.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

Fosun Kite Biotechnology is a joint venture between Shanghai Fosun Pharmaceutical and Kite Pharma, dedicated to the development of immune cell therapy products aimed at treating cancer. The company focuses on innovative pharmaceuticals, particularly through its research into axicabtagene ciloleucel and kite-439. These therapies are designed for the treatment of B-cell lymphomas and leukemias, with an emphasis on delivering high-quality medicines to the medical industry.

Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptor inhibitors and other products, for the treatment of advanced prostate cancer and breast cancer.

Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Glycotest Diagnostics focuses on developing innovative and non-invasive blood tests aimed at detecting liver cancers and fibrosis-cirrhosis in at-risk populations. The company's technology targets individuals suffering from chronic liver diseases, including viral hepatitis and those affected by non-viral hepatitis linked to obesity and metabolic disorders. With over 25 million people in the United States and 800 million worldwide at risk, alongside an additional 1.2 billion facing potential complications from fatty liver disease, Glycotest's diagnostic solutions hold significant promise for improving early detection and treatment options. The platform utilizes proprietary serum biomarkers and assay technology that leverages unique sugar-based disease signal chemistry, allowing for advanced clinical laboratory testing services tailored to patients with serious liver conditions.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

Shanghai LinkedCare Information Technology Co., Ltd. specializes in developing software solutions for dental clinics and medical beauty institutions. Founded in 2015 and based in Shanghai, the company offers a range of products designed to enhance operational efficiency and management standards. Its dental cloud management software includes features such as electronic signatures, member management, treatment planning, clinic analysis, and inventory management. Additionally, LinkedCare provides medical beauty cloud management solutions, which encompass marketing tools, appointment scheduling, and cashier systems. The company's integrated platform aims to fully automate the operations of consumer medical enterprises, facilitating a comprehensive health management process that increases revenue, reduces risks, lowers costs, and improves overall efficiency.

Groupe Tridem Pharma is a pharmaceutical distribution and promotion company based in Escalquens, France, with a focus on the African and Middle Eastern markets. Founded in 1986, the company specializes in the distribution of a wide range of pharmaceutical and para-pharmaceutical products, including tablets, syringes, balms, gels, creams, and soaps. In addition to its distribution services, Tridem Pharma provides multi-product medical sales services, pharmaceutical sales services, and training programs for medical and pharmaceutical sales representatives. The company also assists clients in managing risks associated with medical product usage through its pharmacovigilance services. Tridem Pharma operates regional liaison offices in Africa and functions as a subsidiary of Fosun Pharmaceutical AG.

CytoChip Inc. specializes in the design and manufacture of in vitro diagnostic devices, focusing on point-of-care testing solutions. Founded in 2014 and headquartered in Irvine, California, the company has developed the CHIPNOW SYSTEM, which facilitates various diagnostic tests, including complete blood counts and assessments of liver and kidney functions, using a microfluidic design. One of its flagship products, CitoCBC®, allows for rapid, lab-quality complete blood count results from just a single drop of blood, making it suitable for use in physician offices, pharmacy clinics, and even home care settings. With a commitment to enhancing accessibility to reliable diagnostics, CytoChip collaborates with prominent hospitals to support clinical validation and innovation in testing methods. The company operates a research and development center in California, complemented by an engineering and manufacturing facility in Suzhou, China, positioning itself at the forefront of advancements in point-of-care diagnostic technology.

Breas Medical AB specializes in designing, developing, and manufacturing homecare ventilation and sleep therapy products for both adult and pediatric patients with respiratory issues. Founded in 1991 and based in Molnlycke, Sweden, the company offers a range of medical devices, including continuous positive airway pressure devices, pressure control and support devices, life-support ventilators, and sleep apnea therapy devices. These products are intended to assist patients suffering from conditions like neuromuscular disorders, anatomical defects, and pulmonary diseases. Breas Medical also provides clinical services and distributes its products globally through a network of trained distributors and an online store. The company is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Gland Pharma Limited, founded in 1978 and based in Hyderabad, India, specializes in the development, manufacturing, and marketing of injectable-focused generic liquid parenteral products. The company offers a broad range of injectables, including vials, ampoules, pre-filled syringes, and lyophilized products, with key molecules such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections. Gland Pharma's product portfolio spans various therapeutic categories, including anti-infectives, anesthetics, anti-coagulants, oncology, and more. The company is recognized for its pioneering work in Heparin technology in India and is a leader in the Glycosaminoglycans (GAGs) segment. Gland Pharma primarily serves regulated markets, generating a significant portion of its revenue from the United States, Canada, Europe, and Australia. Additionally, the company provides contract development and manufacturing services to global partners, reinforcing its commitment to quality and innovation in the injectable pharmaceutical sector.

DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.

Spirosure develops and manufactures breath-analysis devices aimed at improving disease diagnosis and management through non-invasive technology. The company focuses on chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and chronic pulmonary hypertension. By utilizing advanced sensors and algorithms, Spirosure's devices enable the detection of biomarkers in patients' breath, which assists medical researchers in diagnosing and monitoring these conditions. Additionally, the technology supports the monitoring of medication adherence for asthma patients, contributing to better management of chronic diseases and enhancing preventative healthcare.

Yaoshibang is a Chinese B2B pharmaceutical trading platform that focuses on empowering participants in the out-of-hospital pharmaceutical market. The company serves a diverse range of stakeholders, including pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions. By leveraging digitalization, Yaoshibang aims to streamline the procurement of pharmaceutical health products and services, ensuring that users can access a wide array of high-quality drugs at fair and transparent prices. The platform transforms traditional pharmaceutical transactions into a digitalized, standardized, and scalable process, enhancing efficiency and safety in the delivery of healthcare products.

Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.

Amerigen Pharmaceuticals Limited, founded in 2007 and headquartered in Suzhou, China, specializes in the development, manufacture, and distribution of generic pharmaceutical products primarily for the United States and China. The company has established a significant presence in the U.S. market with an office in central New Jersey, which oversees various functions including product development, finance, regulatory affairs, and commercial operations. Amerigen's product development initiatives are supported by a skilled team of research and development, quality assurance, and regulatory professionals located across multiple global sites. The company is committed to delivering high-quality generic medications to meet the needs of healthcare providers and patients in these key markets.

Anhui Sunhere Pharmaceutical Excipients Co Ltd specializes in the research, development, production, and sales of pharmaceutical excipients and medical products. The company manufactures a range of excipients such as hypromellose, carmellose calcium, hypromellose phthalate, microcrystalline cellulose, and polyacrylic resin emulsion. Additionally, Anhui Sunhere produces various oral solid preparations, including fillers, adhesives, disintegrants, lubricants, and coating materials. The company is recognized as a prominent player in China's pharmaceutical excipient market, providing essential ingredients for the development of medical products.

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Isfiya, Israel, specializing in the development of a capsule-based system for colorectal cancer screening. The company's flagship product, C-Scan, employs low-dose X-rays to screen for polyps, masses, and colorectal cancers without the need for bowel preparation or invasive procedures. The C-Scan system comprises three components: the C-Scan Cap, an ingestible capsule that captures and transmits structural data; the C-Scan Track, a biocompatible device worn on the patient's back for tracking and data recording; and C-Scan View, software for processing and visualizing the collected clinical data. This innovative approach allows for the detection of clinically significant polyps with accuracy comparable to traditional colonoscopy while eliminating the need for retrieval of the capsule post-examination. Check-Cap aims to market its products in the United States, Europe, Israel, and Japan.

Chindex International, Inc. provides healthcare services in China. The company owns and operates the United Family Healthcare network of private primary care hospitals and affiliated ambulatory clinics in Beijing, Shanghai, Tianjin, and Guangzhou. The company was founded in 1981 and is headquartered in Bethesda, Maryland.

BSC develops a series of software and hardware products. They provide teleconsultation, remote video, remote ECG, telepathology, distance education, and remote ultrasound services.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.

Shenyang Hongqi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical Group, was established in 1964 and specializes in the development, production, and distribution of pharmaceutical products, particularly focusing on anti-tuberculosis drugs. As an active member of the Chinese Anti Tuberculosis Association, the company plays a vital role in combating tuberculosis by providing effective treatment options. Shenyang Hongqi Pharmaceutical is dedicated to healthcare and innovation, demonstrated through its continuous research and development efforts aimed at enhancing drug efficacy and improving accessibility for patients globally. The company also offers a comprehensive suite of tools for managing drug discovery projects, supporting processes from target identification to clinical trials.

Golden Elephant Pharmacy is an online pharmaceutical store.

Hengda Gufen is a shoe and apparel manufacturing and seller company.

Laoniangjiu Catering is a food and beverage company. They offer a business takeaway menu with staple meals, beverages, desserts, delicious soups, and breakfast snacks. They provide chinese-style fast food products that are mainly flavored and can be superimposed on food and beverages.

Salus BioMed is a biomedical company focused on advancing genetic sequencing technology and spatial omics products. It specializes in developing a DNA sequencing platform that features high-definition spatial transcriptomics, which allows for the measurement of gene activity. This technology enhances the ability to diagnose and treat various diseases, positioning Salus BioMed at the forefront of innovative solutions in the biomedical sector.